Security key
98422T209
- Security type / class
- Equity / COM
- Total 13F shares
- 59
- Total 13F value
- $565
- Share change
- -47,695
- SEC-reported price per share
- $9.58
- Number of holders
- 1
- Value change
- -$401,115
- Number of sells
- 1
Report period
Q2 2026
Institutions
1
Top holders
1
XLO full security history
Ownership snapshot
Full 13F holder table
Previous quarter: Q1 2026
Xilio Therapeutics, Inc. SEC filings
Xilio Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 98422T209
Recent filing periods:
Ownership snapshot
Top reported holders of XLO - Xilio Therapeutics, Inc. - COM (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
GILEAD SCIENCES, INC.
Disclosed value leader
GILEAD SCIENCES, INC.
Comparable rows
8/15
Latest evidence
31 Mar 2026
3/4/5
13D/G
13F
Lead comparable stake: 20%
7 rows are not safely comparable across share classes.
13D/G row: GILEAD SCIENCES, INC.
Showing 1-6 of 15 holder rows.
Quick read
GILEAD SCIENCES, INC. leads the comparable SEC ownership view at 20%.
8 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens GILEAD SCIENCES, INC.'s linked filing trail.
Comparable ownership
Top 5
GILEAD SCIENCES, INC.
20%
Bain Capital Life Sciences Fund I...
10%
ORBIMED ADVISORS LLC
10%
Coastlands Capital LP
10%
Sirenia Capital Management LP
9.9%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| GILEAD SCIENCES, INC. |
3/4/5
13D/G
13F
10%+ Owner · Company
|
20%
from 13D/G
|
$21,601,543
67,054,266 shares
mixed-class rows
|
+$1,999,991 | 13 Feb 2026 |
| Bain Capital Life Sciences Fund II, L.P. |
13D/G
BCLS II Equity Opportunities, LP
|
10%
|
$5,584,417
664,021 shares
|
-$47,060,014 | 31 Mar 2026 |
| ORBIMED ADVISORS LLC |
13D/G
|
10%
|
$5,399,220
642,000 shares
|
$0 | 31 Mar 2026 |
| Coastlands Capital LP |
13D/G
|
10%
|
$3,742,248
5,346,069 shares
|
$0 | 04 Dec 2025 |
| Sirenia Capital Management LP |
13D/G
|
9.9%
|
$9,611,469
1,142,862 shares
|
$0 | 31 Mar 2026 |
| AbbVie Inc. |
13D/G
|
9%
|
$3,304,348
4,347,826 shares
|
$0 | 11 Feb 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
1
Shares
59
Rows available
1
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2026 vs Q1 2026 Across Filers
Q1 2026 holders
23
Q2 2026 holders
1
Holder diff
-22
| Investor | Q1 2026 Shares | Q2 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend